>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

74.19 -2.18 (-2.85%) 09/04/2026
Nektar Therapeutics (NKTR)
Performance
Historical returns
1D
-2.85%
1W
3.94%
1M
1.97%
3M
25.09%
6M
4.33%
1Y
106.20%
5Y
-69.15%
Snapshot
Key statistics
Close
74.19
Change
-2.18
Change %
-2.85%
Open
74.67
Day Range
73.64 – 75.63
Volume
601,539
Avg Vol (20d)
530,358
Rel Vol
1.13x
52W Range
33.40 - 109.00
vs 52W High
-31.94%
vs 52W Low
122.13%
Gap
-1.96
Market Cap
USD 2.13B
Beta
1.20
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Bull vs Bear
7 bullish · 5 bearish points
Bullish view
  • FY2025 earnings rose 37.9% to -$164.08M.
  • Holds 14.3% above its 200-day average.
  • Has recovered 111.2% off the 52-week low of $35.12.
  • Outperformed the S&P 500 by 24.7% over the last quarter (+29.4% against +4.7%).
  • The Aug 2026 quarter beat on EPS by $0.74 (37.6% above consensus).
  • Sits 96.8% below the average analyst target of $146.00 across 7 firms.
  • 6 of 7 covering analysts rate the shares a buy.
Bearish view
  • Operating margin compressed to -417.9% in the Jun 2026 quarter from -324.2% a year earlier.
  • Revenue fell 9.3% year on year in the Jun 2026 quarter.
  • Full-year revenue declined 43.9% in FY2025 to $55.23M.
  • Still 26.1% below its 52-week high of $100.35.
  • Revenue in the same quarter came in $294.0K short of consensus.
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Sep 4
2026
$74.19 2.85%Latest
Nektar Therapeutics fell 2.85% to $74.19, its biggest one-day drop in 3 weeks. Roughly 1.8 points were stock-specific — the S&P 500 fell 0.39% while Healthcare peers (XLV) fell 1.04% alongside it. Shares opened with a 2.23% gap down. The move left the stock 26.1% below its 52-week high.
Sep 3
2026
$76.37 4.99%
Nektar Therapeutics rose 4.99% to $76.37, its biggest one-day gain in 2 months and a 1.6σ move against its 60-day volatility. Roughly 3.7 points were stock-specific — the S&P 500 gained 1.05% while Healthcare peers (XLV) rose 0.18% alongside it. Shares opened with a 0.92% gap up, closed near the session high (93% of the day's range), reclaimed their 20-day moving average and marked a 3rd consecutive advance. The move added $120.0M of market value.
Aug 14
2026
$73.02 3.82%Earnings
Nektar Therapeutics fell 3.82% to $73.02, its biggest one-day drop in 4 weeks. This was largely stock-specific: the S&P 500 fell 0.20% while Healthcare peers (XLV) fell 0.60% that session, leaving about 3.2 points of the move unexplained by its sector. Shares opened with a 2.53% gap down. It came 1 session after the quarterly print.
Aug 10
2026
$74.86 2.12%Earnings
Nektar Therapeutics fell 2.12% to $74.86, its biggest one-day drop in 3 weeks, though on light volume (0.7× the 20-day average). This was largely stock-specific: the S&P 500 gained 0.01% while Healthcare peers (XLV) rose 1.84% that session, leaving about 2.1 points of the move unexplained by the market after adjusting for a 1.20 beta. It came 2 sessions after the Q2 2026 print.
Aug 7
2026
$76.48 4.13%Earnings
Nektar Therapeutics rose 4.13% to $76.48, its biggest one-day gain in 3 weeks. This was largely stock-specific: the S&P 500 gained 0.57% while Healthcare peers (XLV) rose 0.58% that session, leaving about 3.4 points of the move unexplained by the market after adjusting for a 1.20 beta. Shares opened with a 1.50% gap up, closed near the session high (86% of the day's range) and marked a 4th consecutive advance. This was the first session after Q2 2026 results. The move added $100.2M of market value.
Aug 6
2026
$73.45 0.49%Pre-Earnings
Nektar Therapeutics rose 0.49% to $73.45, though on light volume (0.6× the 20-day average). Shares marked a 3rd consecutive advance. The session traded into Q2 2026 results, released after the close that evening.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month70.00 +5.99%
on 08/31/26
Open 73.45
77.22 -3.92%
on 08/13/26
+0.74 (+1.01%)
since 08/06/26
3-Month54.13 +37.06%
on 06/09/26
Open 57.32
77.23 -3.94%
on 07/07/26
+16.87 (+29.43%)
since 06/05/26
6-Month54.13 +37.06%
on 06/09/26
Open 70.70
109.00 -31.94%
on 04/20/26
+3.49 (+4.94%)
since 03/06/26
YTD33.40 +122.13%
on 01/30/26
Open 43.42
109.00 -31.94%
on 04/20/26
+30.77 (+70.87%)
since 01/02/26
52-Week31.85 +132.94%
on 09/04/25
Open 35.98
109.00 -31.94%
on 04/20/26
+38.21 (+106.20%)
since 09/04/25
5-Year6.19 +1,098.55%
on 11/13/23
Open 224.25
290.55 -74.47%
on 09/27/21
-150.06 (-66.92%)
since 08/27/21
New Highs
Historical highs
5-Day
3×
-2.85% from peak
1-Month
0×
-2.99% from peak
3-Month
11×
-2.99% from peak
6-Month
12×
-26.07% from peak
YTD
17×
-26.07% from peak
52-Week
31×
-26.07% from peak
2-Year
43×
-26.07% from peak
3-Year
54×
-26.07% from peak
5-Year
13×
-73.75% from peak
10-Year
51×
-95.44% from peak
Financial SnapshotFY 2025
Full financials
Revenue
USD 55.23M
-43.9% YoY
Net Income
-USD 164.08M
+37.9% YoY
EPS
-9.73
+12.1% YoY
Gross Margin
100.0%
Operating Margin
-236.8%
Net Margin
-297.1%
EBITDA
-USD 137.00M
Free Cash Flow
-USD 208.68M
-377.8% margin
ROE
-182.6%
ROA
-58.5%
Debt / Equity
1.66x
net debt USD 133.79M
Cash & Equiv.
USD 15.12M
News
All news
08/28 16:15 ET · prnewswire.com
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common stock and...
08/25 08:30 ET · prnewswire.com
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease...
08/14 14:22 ET · seekingalpha.com
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
Nektar Therapeutics maintains a Strong Buy rating, driven by REZPEG's late-stage development in atopic dermatitis [AD] and alopecia areata [AA]. The Phase 3 ZENITH AD program is underway, with three pivotal studies targeting moderate-to-severe AD subpopulations; topline data is expected mid-2028....
08/14 12:05 ET · zacks.com
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.
08/13 23:27 ET · seekingalpha.com
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
08/13 22:04 ET · marketbeat.com
Nektar Therapeutics Q2 Earnings Call Highlights
Nektar Therapeutics NASDAQ: NKTR said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting...
08/13 18:36 ET · zacks.com
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $2.06. This compares to a loss of $2.78 per share a year ago.
08/13 16:15 ET · prnewswire.com
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities...

Market News ×
Loading news…